We are a pharmaceutical company discovering and developing novel drug candidates to treat inflammation and blood cancers. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
We are a pharmaceutical company discovering and developing novel drug candidates to treat inflammation and blood cancers. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- 887 Great Northern Way BC Vancouver
- City
- Vancouver
- Region
- British Columbia
- Postal Code
- V5T 4T5
- Country
- Canada